Reference number : GC-2017-Q2-00359, amendment number : , agreement type : G, recipient legal name : Gray, Bonnie (Simon Fraser University), recipient country : CA, recipient province : nan, recipient city : British Columbia|Colombie-Britannique, recipient postal code : nan, program name english : Engage Grants for Universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Extem supplies research grade mesenchymal stem cells (MSCs) to the health research community and is_x000D_
looking to differentiate themselves by providing a proprietary human derived growth media. MSCs have many_x000D_
applications that are important to the future health of Canadians, such as: applications in tissue engineering and_x000D_
regenerative medicine; drug screening using human tissues prior to clinical trials; and treatment of disease by_x000D_
modulating (enhancing or suppressing) the immune system. MSCs are typically grown in fetal bovine serum_x000D_
(FBS), derived from cows. However, in order to avoid xenotropic complications, the stem cell industry is_x000D_
moving away from products that are derived from non-human species. Other disadvantages of FBS include:_x000D_
batch to batch variability; unexpected cell growth characteristics; and contamination issues. A better_x000D_
standardized human derived solution would solve many of these problems. Pooled Platelet Lysate (PPL) has_x000D_
been identified as a viable alternative to FBS. PPL is produced by means of double centrifugation (DC) of_x000D_
whole blood. However, existing methods of producing PPL lack rigorous quality control, standardization, and_x000D_
can activate cells. For example, DC-based PPL can result in an up to 50% loss in cell viability due to activation_x000D_
of cells under fluid shear stress. Extem needs to develop a more economical solution that integrates beneficial_x000D_
quality control and standardization procedures. Extem and microinstrumentation expert Dr. Gray at Simon_x000D_
Fraser University (SFU) propose a low shear, high throughput scalable microfluidic whole blood sorter with_x000D_
the goal of optimizing designs to result in as many viable platelets as possible over a given time period (high_x000D_
throughput). Individual chips will be optimized both individually and for use in arrays to increase throughput._x000D_
Chips will be designed with the goal of eventual mass production, with manufacturing constraints considered_x000D_
in all phases of device design. The development of such a technology will allow Extem and Canadian health_x000D_
researchers to remain leaders in the production and application of stem cells by providing MSCs grown in a_x000D_
cost-effective human-derived media., program purpose french : Extem supplies research grade mesenchymal stem cells (MSCs) to the health research community and is_x000D_
looking to differentiate themselves by providing a proprietary human derived growth media. MSCs have many_x000D_
applications that are important to the future health of Canadians, such as: applications in tissue engineering and_x000D_
regenerative medicine; drug screening using human tissues prior to clinical trials; and treatment of disease by_x000D_
modulating (enhancing or suppressing) the immune system. MSCs are typically grown in fetal bovine serum_x000D_
(FBS), derived from cows. However, in order to avoid xenotropic complications, the stem cell industry is_x000D_
moving away from products that are derived from non-human species. Other disadvantages of FBS include:_x000D_
batch to batch variability; unexpected cell growth characteristics; and contamination issues. A better_x000D_
standardized human derived solution would solve many of these problems. Pooled Platelet Lysate (PPL) has_x000D_
been identified as a viable alternative to FBS. PPL is produced by means of double centrifugation (DC) of_x000D_
whole blood. However, existing methods of producing PPL lack rigorous quality control, standardization, and_x000D_
can activate cells. For example, DC-based PPL can result in an up to 50% loss in cell viability due to activation_x000D_
of cells under fluid shear stress. Extem needs to develop a more economical solution that integrates beneficial_x000D_
quality control and standardization procedures. Extem and microinstrumentation expert Dr. Gray at Simon_x000D_
Fraser University (SFU) propose a low shear, high throughput scalable microfluidic whole blood sorter with_x000D_
the goal of optimizing designs to result in as many viable platelets as possible over a given time period (high_x000D_
throughput). Individual chips will be optimized both individually and for use in arrays to increase throughput._x000D_
Chips will be designed with the goal of eventual mass production, with manufacturing constraints considered_x000D_
in all phases of device design. The development of such a technology will allow Extem and Canadian health_x000D_
researchers to remain leaders in the production and application of stem cells by providing MSCs grown in a_x000D_
cost-effective human-derived media., agreement title english : Low-shear, scalable microfluidic sorting of platelets and leukocytes for pooled platelet lysate, agreement title french : Low-shear, scalable microfluidic sorting of platelets and leukocytes for pooled platelet lysate, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-08-23, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada